Restoring immune competence through T cell regeneration
The Problem
Cancer treatments (chemo, radiation, HSCT transplant) impair immune recovery
Incomplete immune recovery weakens therapy efficacy and leaves patients vulnerable to relapse, infections
Our Science
The Solution
Novel platform generates progenitor T (ProT) cells to restore immune function to treat cancer and beyond.
Off-the-shelf scalability
Cost efficiency vs. CAR-T
Potential for broad use
Clinical Strategy
Allo HSCT → solid tumors → universal iPSC
Near-term milestones derisk the platform
FIH trials expected in 2027
NEXT GENERATION CELL THERAPY
Rejuvenating the immune system’s master organ by delivering ProT cells to treat cancer, autoimmune diseases, and beyond
Our Team
Carter Cliff, CEO
Mahmood Mohtashami, Director of Research
Juan Carlos Zuñiga-Pflücker
Board of Directors
Monet Goode
Eleanor Parks
Emmet Marsh
Our Investors
